Dactinomycin

證據等級: L5

預測適應症: 9 個

Dactinomycin: From Pediatric Solid Tumors to Relapsing-Remitting Multiple Sclerosis

One-Sentence Summary

Dactinomycin (Actinomycin D) is a cytotoxic intercalating antibiotic established in pediatric oncology, used as a cornerstone agent in standard regimens for rhabdomyosarcoma, Wilms’ tumor, and gestational trophoblastic neoplasia. The TxGNN model predicts it may be effective for Relapsing-Remitting Multiple Sclerosis (RRMS), with 0 clinical trials and 0 publications currently supporting this repurposing direction.

Quick Overview

Item	Content
Original Indication	Pediatric solid tumors (rhabdomyosarcoma, Wilms’ tumor, gestational trophoblastic neoplasia)
Predicted New Indication	Relapsing-Remitting Multiple Sclerosis
TxGNN Prediction Score	99.58%
Evidence Level	L5
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this dataset. Based on established pharmacological knowledge, Dactinomycin (Actinomycin D) is a DNA-intercalating antibiotic that inserts between guanine-cytosine base pairs and physically blocks RNA polymerase, halting RNA transcription. This mechanism confers potent, non-selective cytotoxic activity against all rapidly proliferating cells, forming the pharmacological basis for its long-standing use in pediatric oncology — particularly in the VAC combination regimen (vincristine + actinomycin D + cyclophosphamide).

Relapsing-Remitting Multiple Sclerosis is an autoimmune demyelinating disease driven by autoreactive T- and B-lymphocytes that attack the myelin sheath of the central nervous system. Theoretically, a cytotoxic agent like Dactinomycin could suppress this autoimmune cascade through non-selective lymphocyte depletion. This indirect mechanistic pathway likely explains the TxGNN model’s prediction — shared immune-related nodes in the knowledge graph may create an apparent connection between Dactinomycin and RRMS.

However, the clinical rationale is weak. Established RRMS disease-modifying therapies (natalizumab, fingolimod, ocrelizumab, cladribine) achieve targeted immunomodulation with substantially more favorable and predictable safety profiles. Dactinomycin’s severe toxicity burden — dose-limiting myelosuppression, hepatotoxicity, mucositis, and known carcinogenicity — would be clinically disproportionate for a chronic, non-malignant condition. The high TxGNN score most likely reflects indirect knowledge graph connectivity rather than true biological plausibility for RRMS.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Dactinomycin is currently not registered in India. No marketing authorizations are on record (0 licenses).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Intercalating antibiotic — Actinomycin class)
Myelosuppression Risk	High — bone marrow suppression is a dose-limiting toxicity; neutropenia, thrombocytopenia, and anemia are expected and common adverse effects
Emetogenicity Classification	Moderate to high
Monitoring Items	Complete blood count with differential (CBC/diff), liver function tests (AST, ALT, bilirubin), renal function, signs of oral mucositis and veno-occlusive disease (particularly in young children)
Handling Protection	Must follow cytotoxic / hazardous drug handling regulations: dedicated preparation area, appropriate PPE (gloves, gown, eye protection) during compounding and administration

Safety Considerations

Drug Interactions (164 total interactions identified; key interactions below):

Severity	Interacting Drug	Notes
Major	Deferiprone	Additive risk of agranulocytosis and severe neutropenia; concurrent use should be avoided
Major	Samarium (153Sm) lexidronam	Additive myelosuppression; bone marrow recovery must be confirmed before combining
Moderate	Mercaptopurine	Additive hematologic toxicity; dose adjustment and close CBC monitoring required
Moderate	Palifermin	Palifermin should not be administered within 24 hours before or after cytotoxic chemotherapy (increased mucosal toxicity risk)
Moderate	Strontium chloride Sr-89	Additive bone marrow suppression; hematologic parameters must be adequate before use
Moderate	Fostamatinib	Increased risk of hematologic adverse events
Moderate	Roflumilast	Potential additive immunosuppressive effect
Moderate	Chloramphenicol	Additive myelosuppressive potential
Minor	Levofloxacin	Minor interaction; monitor for overlapping adverse effects

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical trial or published literature evidence supporting Dactinomycin in relapsing-remitting multiple sclerosis. The mechanistic link is speculative and relies on indirect knowledge graph connectivity; furthermore, the drug’s severe cytotoxicity profile creates a clearly unfavorable risk-benefit ratio compared to all currently approved RRMS disease-modifying therapies.

To proceed, the following is needed:

Preclinical studies (in vitro autoimmune models or EAE mouse model) specifically evaluating Dactinomycin’s immunomodulatory effects in a demyelinating disease context
Verified mechanism of action data (DrugBank API or primary pharmacology literature) to confirm whether low-dose immunosuppression is mechanistically plausible without unacceptable toxicity
A comparative risk-benefit analysis against current standard-of-care RRMS therapies to establish whether any therapeutic window exists
Toxicogenomic or dose-finding data exploring sub-cytotoxic immunosuppressive dosing regimens

Multi-indication note: This report covers the top-ranked TxGNN prediction (Rank 1: RRMS, L5, Hold). This evidence pack contains 9 predicted indications in total. Significantly stronger clinical evidence exists for Dactinomycin in rhabdomyosarcoma subtypes (Rank 5: parameningeal embryonal RMS — L2, Proceed with Guardrails, supported by Phase 3 RCT data) and liver sarcoma (Rank 7 — L3, Proceed with Guardrails, with 1 Phase 3 trial and 20 publications). Separate focused reports for these higher-evidence indications are recommended.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.